|
CENTERS FOR MEDICARE &
MEDICAID SERVICES (CMS)
Special
Edition – Wednesday, December 9, 2020
|
In Case You Missed It: CMS Announces Guidance for Medicare
Coverage of COVID-19 Antibody Treatment
On December 9, CMS posted updates to FAQs and
an infographic about coverage and payment for monoclonal antibodies to treat
COVID-19. The FAQs include general payment and billing guidance for these
products, including questions on different setting types. The infographic has
key facts about expected Medicare payment to providers and information about
how Medicare beneficiaries can receive these innovative COVID-19 treatments
with no cost-sharing during the public health emergency (PHE). CMS’ November
10, 2020 announcement about coverage of monoclonal
antibody therapies allows a broad range of providers and suppliers, including
freestanding and hospital-based infusion centers, home health agencies,
nursing homes, and entities with whom nursing homes contract, to administer this
treatment in accordance with the Food & Drug Administration’s Emergency
Use Authorization (EUA), and bill Medicare to administer these infusions.
Currently, two monoclonal antibody therapies have received EUA’s for
treatment of COVID-19. For More Information:
Like our newsletter? Have
suggestions? Please let us know!
|
No comments:
Post a Comment